Novo Nordisk’s stock hit a 52-week low after its REDEFINE 4 trial failed to demonstrate non-inferiority in weight loss compared to Eli Lilly’s tirzepatide, marketed under the Zepbound and Mounjaro brands.The trial showed a weight loss of 20.2% with CagriSema versus 23.6% with tirzepatide, leading to a significant drop in Novo Nordisk shares.The REDEFINE 4 trial involved 809 subjects over 84 weeks, and while CagriSema demonstrated a safe profile, the results did not meet expectations.William Blair analyst An ...

Core Viewpoint - Cantor Fitzgerald believes that Viking Therapeutics' GLP-1 diet drug VK2735 has the potential to become a "multi-blockbuster," significantly boosting the company's stock value [1][4]. Group 1: Stock Performance - Viking Therapeutics' shares increased by 12.5% on Tuesday following positive endorsements from Wall Street analysts [1]. - The stock saw a rise after Truist Securities analyst Joon Lee lowered his price target but predicted benefits from phase 3 clinical trial news for VK2735 [2]. Group 2: Analyst Predictions - Cantor Fitzgerald's analyst Steven Seedhouse predicts that Viking's stock price could quadruple from $29 to $104 within a year, emphasizing a strong buy recommendation [2]. - Seedhouse's thesis is centered on VK2735, which is entering phase 3 development for general obesity, and he believes that even the injectable form alone could more than triple the stock's value [3]. Group 3: Drug Comparison and Potential - Seedhouse argues that VK2735's formulation is superior to Eli Lilly's tirzepatide, suggesting it will outperform Lilly's Zepbound and Mounjaro [4]. - The potential development of a VK2735 pill, which would eliminate the need for injections, is seen as an additional positive factor, with phase 2 data expected in the second quarter of 2025 [3].